Tau phosphorylation sites work in concert to promote neurotoxicity in vivo.

Tau is a microtubule binding protein implicated in a number of human neurodegenerative disorders, including Alzheimer's disease. Phosphorylation of serine-proline/threonine-proline sites, targeted by proline-directed kinases, coincides temporally with neurodegeneration in the human diseases. Recently, we demonstrated that this unique group of serines and threonines has a critical role in controlling tau toxicity in a Drosophila model of tauopathy. Here, we use a combination of genetic and biochemical approaches to examine these sites individually and to determine which of them is primarily responsible for controlling tau neurotoxicity. Despite the importance placed on individual phosphoepitopes and their contributions to disease pathogenesis, our results indicate that no single phosphorylation residue plays a dominant role in controlling tau toxicity. These findings suggest that serine-proline/threonine-proline sites cooperate to mediate neurodegeneration in vivo.

[1]  J. Shulman,et al.  S/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila , 2007, Journal of neuroscience research.

[2]  Tudor A. Fulga,et al.  Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo , 2007, Nature Cell Biology.

[3]  D. Dias-Santagata,et al.  Oxidative stress mediates tau-induced neurodegeneration in Drosophila. , 2007, The Journal of clinical investigation.

[4]  M. Goedert,et al.  Sequential phosphorylation of tau protein by cAMP‐dependent protein kinase and SAPK4/p38δ or JNK2 in the presence of heparin generates the AT100 epitope , 2006, Journal of neurochemistry.

[5]  E. Skoulakis,et al.  Cell type‐specific processing of human Tau proteins in Drosophila , 2006, FEBS letters.

[6]  J. Shulman,et al.  TOR-Mediated Cell-Cycle Activation Causes Neurodegeneration in a Drosophila Tauopathy Model , 2006, Current Biology.

[7]  F. Liu,et al.  Post-translational modifications of tau protein in Alzheimer’s disease , 2005, Journal of Neural Transmission.

[8]  W. Noble,et al.  Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Ravid,et al.  Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology , 2005, Journal of neurochemistry.

[10]  B. Winblad,et al.  Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain , 2004, Neuroreport.

[11]  S. Lovestone,et al.  GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila , 2004, Molecular Psychiatry.

[12]  B. Lu,et al.  PAR-1 Kinase Plays an Initiator Role in a Temporally Ordered Phosphorylation Process that Confers Tau Toxicity in Drosophila , 2004, Cell.

[13]  J. Shulman,et al.  Genetic modifiers of tauopathy in Drosophila. , 2003, Genetics.

[14]  H. Braak,et al.  Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. , 2003, The American journal of pathology.

[15]  A. Delacourte,et al.  Phosphorylated serine 199 of microtubule-associated protein tau is a neuronal epitope abundantly expressed in youth and an early marker of tau pathology , 2003, Acta Neuropathologica.

[16]  W. Albers,et al.  A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells. , 2002, European journal of biochemistry.

[17]  D. Geschwind,et al.  Human Wild-Type Tau Interacts with wingless Pathway Components and Produces Neurofibrillary Pathology in Drosophila , 2002, Neuron.

[18]  Joshua M. Shulman,et al.  Tauopathy in Drosophila: Neurodegeneration Without Neurofibrillary Tangles , 2001, Science.

[19]  G. Jicha,et al.  cAMP-Dependent Protein Kinase Phosphorylations on Tau in Alzheimer’s Disease , 1999, The Journal of Neuroscience.

[20]  T. Shea,et al.  The Order of Exposure of Tau to Signal Transduction Kinases Alters the Generation of “AD-Like” Phosphoepitopes , 1999, Cellular and Molecular Neurobiology.

[21]  G. Jicha,et al.  Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease , 1999, Journal of neuroscience research.

[22]  E. Mandelkow,et al.  Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. , 1998, European journal of biochemistry.

[23]  G. Jicha,et al.  A Conformation‐ and Phosphorylation‐Dependent Antibody Recognizing the Paired Helical Filaments of Alzheimer's Disease , 1997, Journal of neurochemistry.

[24]  G. Jicha,et al.  Alz‐50 and MC‐1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau , 1997, Journal of neuroscience research.

[25]  J. Kuret,et al.  The Structural Basis of Monoclonal Antibody Alz50's Selectivity for Alzheimer's Disease Pathology* , 1996, The Journal of Biological Chemistry.

[26]  D. Dickson,et al.  Neurodegenerative disorders with extensive tau pathology: A comparative study and review , 1996, Annals of neurology.

[27]  M. Hasegawa,et al.  Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments. , 1996, Dementia.

[28]  P. Davies,et al.  Mitotic mechanisms in Alzheimer's disease? , 1996, The Journal of cell biology.

[29]  E. Vanmechelen,et al.  Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205 , 1995, Neuroscience Letters.

[30]  Khadija Iqbal,et al.  Rapid Alzheimer‐like phosphorylation of tau by the synergistic actions of non‐proline‐dependent protein kinases and GSK‐3 , 1995, FEBS letters.

[31]  M. Goedert,et al.  Monoclonal antibody PHF‐1 recognizes tau protein phosphorylated at serine residues 396 and 404 , 1994, Journal of neuroscience research.

[32]  J. Trojanowski,et al.  τ Phosphorylation in Human, Primate, and Rat Brain: Evidence that a Pool of τ Is Highly Phosphorylated In Vivo and Is Rapidly Dephosphorylated In Vitro , 1994, Journal of neurochemistry.

[33]  J. Trojanowski,et al.  Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau , 1994, Neuron.

[34]  P. Cohen,et al.  Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. , 1994, The Biochemical journal.

[35]  Virginia M. Y. Lee,et al.  Recognition of the minimal epitope of monoclonal antibody Tau‐1 depends upon the presence of a phosphate group but not its location , 1993, Journal of neuroscience research.

[36]  C. W. Scott,et al.  Phosphorylation of recombinant tau by cAMP-dependent protein kinase. Identification of phosphorylation sites and effect on microtubule assembly. , 1993, The Journal of biological chemistry.

[37]  S. Yen,et al.  Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments , 1992, Brain Research.

[38]  E. Mandelkow,et al.  The switch of tau protein to an Alzheimer‐like state includes the phosphorylation of two serine‐proline motifs upstream of the microtubule binding region. , 1992, The EMBO journal.

[39]  J. Trojanowski,et al.  A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. , 1991, Science.

[40]  M. Kirschner,et al.  Phosphorylation of microtubule‐associated protein tau: identification of the site for Ca2(+)‐calmodulin dependent kinase and relationship with tau phosphorylation in Alzheimer tangles. , 1990, The EMBO journal.

[41]  P. Davies,et al.  A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[42]  A. Delacourte,et al.  Abnormal tau species are produced during Alzheimer's disease neurodegenerating process , 1989, FEBS letters.

[43]  B T Hyman,et al.  Alz‐50 Antibody recognizes alzheimer‐related neuronal changes , 1988, Annals of neurology.

[44]  J. Baudier,et al.  Phosphorylation of tau proteins to a state like that in Alzheimer's brain is catalyzed by a calcium/calmodulin-dependent kinase and modulated by phospholipids. , 1987, The Journal of biological chemistry.

[45]  J. Trojanowski,et al.  Neurodegenerative tauopathies. , 2001, Annual review of neuroscience.